| |
Total (n = 63)
|
ELN+
|
ELN–
|
p value
|
|---|
|
n = 30 (47.6 %)
|
n = 33 (52.4 %)
|
|---|
|
Female, n (%)
|
41 (65)
|
21 (70)
|
20 (61)
|
NS
|
|
Age (years)
|
59 (49; 69)
|
56 (50; 64)
|
62 (49; 70)
|
NS
|
|
Disease duration (years)
|
12.0 (4.8; 17.8)
|
9.1 (3.9; 17.8)
|
13.1 (10.5; 17.8)
|
NS
|
|
Tender joint count
|
3 (1; 10)
|
4 (2; 10)
|
2 (1; 10)
|
NS
|
|
Swollen joint count
|
5 (2; 9)
|
6 (2; 10)
|
3 (1; 8)
|
NS
|
|
C-reactive protein (mg/dL)
|
2.4 (1.1; 4.2)
|
2.7 (1.4; 5.1)
|
2.1 (0.7; 3.8)
|
NS
|
|
ESR (mm/h)
|
33 (19; 67)
|
35 (19; 67)
|
31 (18; 53)
|
NS
|
|
DAS28
|
4.4 (3.3; 5.5)
|
5.1 (3.9; 5.7)
|
4.0 (3.0; 4.9)
|
0.039
|
|
RF (IU)
|
128 (24; 257)
|
138 (61; 256)
|
74 (17; 325)
|
NS
|
|
ACPA (IU)
|
254 (0; 782)
|
257 (0; 701)
|
251 (0; 822)
|
NS
|
|
Number of DMARDs taken before biopsy
|
2 (1; 3)
|
2 (1; 3)
|
2 (1; 4)
|
NS
|
|
Number (%) of patients taking oral steroidsa
|
46 (73)
|
23 (76)
|
23 (70)
|
NS
|
- Data are expressed as median (IQR), or frequency (%)
-
NS nonsignificant, ESR erythrocyte sedimentation rate, DAS28 28-item disease activity score, RF rheumatoid factor, IU international units, ACPA anti-citrullinated peptide/protein antibodies, DMARDs, disease-modifying antirheumatic drugs
-
aAll of them ≤ 5 mg prednisone
